LIXT Logo

Lixte Biotechnology Holdings, Inc. (LIXT) 

NASDAQ
Market Cap
$3.67M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
596 of 774
Rank in Industry
321 of 433

Largest Insider Buys in Sector

LIXT Stock Price History Chart

LIXT Stock Performance

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically …

Insider Activity of Lixte Biotechnology Holdings, Inc.

Over the last 12 months, insiders at Lixte Biotechnology Holdings, Inc. have bought $0 and sold $0 worth of Lixte Biotechnology Holdings, Inc. stock.

On average, over the past 5 years, insiders at Lixte Biotechnology Holdings, Inc. have bought $538,785 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,527 shares for transaction amount of $13,873 was made by Bernards Rene (director) on 2023‑10‑03.

List of Insider Buy and Sell Transactions, Lixte Biotechnology Holdings, Inc.

2023-10-03Purchasedirector
5,527
0.2398%
$2.51$13,873-13.14%
2023-10-03PurchasePresident and CEO
10,000
0.484%
$2.80$28,000-13.14%
2023-10-02Purchasedirector
4,473
0.1771%
$2.29$10,243-3.44%
2022-12-30Purchasedirector
10,000
0.0609%
$0.49$4,900+2.16%
2022-12-15Purchasedirector
15,000
0.0893%
$0.51$7,650-3.87%
2022-12-12Purchasedirector
10,000
0.0632%
$0.61$6,100-14.60%
2022-12-09PurchaseVice President and COO
1,112
0.0071%
$0.63$701-16.14%
2022-11-22PurchaseVice President and COO
2,484
0.0154%
$0.56$1,391-4.40%
2022-11-21PurchaseVice President and COO
1,457
0.0092%
$0.56$816-1.89%
2022-11-21Purchasedirector
5,000
0.0325%
$0.58$2,876-1.89%
2022-11-18PurchaseVice President and COO
16,207
0.0994%
$0.56$9,125-5.00%
2022-11-17PurchaseVice President and COO
4,852
0.0307%
$0.54$2,619+2.22%
2022-11-14Purchasedirector
52,500
0.3141%
$0.53$27,825-1.43%
2020-11-30PurchasePresident and CEO
21,100
0.0394%
$4.75$100,225-24.01%
2020-11-30Purchase10 percent owner
52,632
0.0984%
$4.75$250,002-24.01%
2020-11-30Purchase10 percent owner
105,264
0.1968%
$4.75$500,004-24.01%
2020-11-30Purchasedirector
52,632
0.0984%
$4.75$250,002-24.01%
2020-11-30Purchasedirector
21,053
0.0394%
$4.75$100,002-24.01%
2020-11-30Purchasedirector
21,053
0.0394%
$4.75$100,002-24.01%
2020-11-30Purchase10 percent owner
42,105
0.0787%
$4.75$199,999-24.01%

Insider Historical Profitability

<0.0001%
Riggs Arthur10 percent owner
6110000
271.6413%
$1.6330
Kovach John SPresident and CEO
1540183
68.4742%
$1.6310<0.0001%
GREENBERG ROBERT10 percent owner
994299
44.205%
$1.6310<0.0001%
Schwartzberg Gil10 percent owner
247775
11.0157%
$1.6330<0.0001%
Yen Yundirector
52632
2.3399%
$1.6310<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.